Circulating tumor DNA (ctDNA) has emerged as a useful diagnostic and prognostic
biomarker in many cancers. Here, we conducted a study to investigate the potential use of …

Screening for early‐stage disease is vital for reducing colorectal cancer (CRC)‐related
mortality. Methylation of circulating tumor DNA has been previously used for various types of …

Abstract BACKGROUND Circulating tumor DNA (ctDNA) has emerged as a good candidate
for tracking tumor dynamics in different cancer types, potentially avoiding repeated tumor …

Importance Detection of molecular residual disease and risk stratification as early as
possible may improve the treatment of patients with cancer. Efficient pragmatic tests are …

Colorectal cancer (CRC), the second leading cause of cancer mortality, constitutes a
significant global health burden. An accurate, noninvasive detection method for CRC as …

Aberrant DNA methylation has shown promise as a biomarker for the early detection of
cancer. To discover novel genes frequently methylated at an early stage in colorectal cancer …

An effective blood-based method for the diagnosis and prognosis of hepatocellular
carcinoma (HCC) has not yet been developed. Circulating tumour DNA (ctDNA) carrying …

Background Targeted methylation sequencing of plasma cell-free DNA (cfDNA) has a
potential to expand liquid biopsies to patients with tumors without detectable oncogenic …

Colorectal cancer (CRC) is one of the most common and deadliest cancers worldwide.
Patient survival can be greatly improved if cancerous lesions are detected early. 1 Despite a …

Colorectal cancer (CRC) is a serious public health problem and non-invasive biomarkers
improving diagnosis or therapy are strongly required. Circulating cell-free DNA (cfDNA) has …